EHA 2026: Acalabrutinib Shows Durable Responses in Frail and Elderly Patients with CLL

Updated results from the CLL-Frail trial presented at EHA 2026 show durable responses, sustained improvements in self-assessed frailty and quality of life, and an overall survival of more than 80% after three years in patients aged 80 years or older or living with frailty. Florian Simon, study physician at the German CLL Study Group, also discusses why honest discussions about treatment goals, benefits, and safety remain essential.